C. Ola Landgren and colleagues discuss adapting to a field transformed by new immunotherapy drugs and targeted therapies and how to best combine treatments
Phase 2 trial suggests pre-surgical immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.